T
TScan Therapeutics, Inc. (TCRX)
NGM – Real vaqt narxi. Valyuta: USD
1.15
-0.03 (-2.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.15
-0.00 (-0.08%)
Bozor oldidan: May 13, 2026, 8:36 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
1.15
-0.03 (-2.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.15
-0.00 (-0.08%)
Bozor oldidan: May 13, 2026, 8:36 AM EDT
TScan Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Amerika Qo'shma Shtatlarida bemorlarni saratonni davolash uchun T-hujayra retseptorlari bilan muhandislik qilingan T-hujayra (TCR-T) terapiyalarini ishlab chiqadi. Kompaniyaning asosiy mahsuloti TSC-101 bo'lib, u o'tkir miyeloid leykemiya (OML), mielodisplastik sindrom (MDS) va o'tkir limfoblastik leykemiya (ALL) bilan og'rigan bemorlarni davolash uchun mo'ljallangan, ular allogenik gematopoez hujayra transplantatsiyasidan (HCT) o'tayotganlarida, bu I bosqich klinik sinovda bo'lib, qoldiq kasallikni yo'qotadi va donor ximerizmini rag'batlantiradi. Kompaniya, shuningdek, epitoplarga qaratilgan allogenik va donor tomonidan olingan TCR-T terapiyasi nomzodlari bo'lgan TSC-102-A01 va TSC-102-A03larni ishlab chiqadi. Bundan tashqari, kompaniya qattiq o'smalarni davolash uchun TSC-200, TSC-201, TSC-202, TSC-203 va TSC-204ni ishlab chiqadi. Kompaniya Kron kasalligi bilan og'rigan bemorlarda T-hujayralari tomonidan tan olingan antigenlarni aniqlash uchun Amgen Inc. bilan ilmiy-tadqiqot hamkorligi va litsenziyalash shartnomasiga ega. TScan Therapeutics, Inc. 2018 yilda ro'yxatga olingan va shtab-kvartirasi Uolthem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Chrystal U. Louis M.D., M.P.H. | Chief Medical Officer |
| Dr. Gavin MacBeath Ph.D. | CEO & Director |
| Dr. Shrikanta Chattopadhyay M.D. | Senior VP & Head of Translational Medicine |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal & Strategy Officer and Company Secretary |
| Mr. Jason A. Amello CPA | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer |
| Mr. Jim Murray | Chief Development Operations Officer |
| Mr. Ray Lockard M.B.A. | Chief Manufacturing & Quality Officer |
| Mr. Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board |
| Ms. Ann Hargraves | Chief Human Resources Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | tcrx-20260506.htm |
| 2026-05-06 | 10-Q | tcrx-20260331.htm |
| 2026-04-17 | DEF 14A | d26976ddef14a.htm |
| 2026-04-17 | ARS | d26610dars.pdf |
| 2026-04-07 | PRE 14A | d26976dpre14a.htm |
| 2026-04-02 | 8-K | d923169d8k.htm |
| 2026-03-04 | 8-K | tcrx-20260304.htm |
| 2026-01-12 | 8-K | d91709d8k.htm |
| 2025-11-26 | 8-K | d41366d8k.htm |
| 2025-11-12 | 8-K | tcrx-20251112.htm |